56
Participants
Start Date
April 6, 2021
Primary Completion Date
March 18, 2022
Study Completion Date
March 18, 2022
CM310
300 mg every two weeks
Placebo
300 mg every two weeks
Beijing Chaoyang Hospital, CMU, Beijing
Beijing Hospital, Beijing
Beijing Renmin Hospital, Beijing
Beijing Tongren Hospital, CMU, Beijing
First Affiliated Hospital of Chongqing Medical University, Chongqing
Jingzhou Central Hospital, Jingzhou
Renmin Hospital of Wuhan University, Wuhan
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan
Third Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of Nanchang University, Nanchang
Affiliated Hospital of Qingdao University, Qingdao
Yantai Yuhuangding Hospital, Yantai
Shandong Second Provincial General Hospital (Shandong ENT hospital), Jinan
Renji Hospital of Shanghai Jiaotong University School of Medicine, Shanghai
Tongji Hospital of Tongji University, Shanghai
Second Hospital of Shanxi Medical University, Taiyuan
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu
West China Hospital of Sichuan University, Chengdu
Zhejiang Provincial People's Hospital, Hangzhou
Lead Sponsor
Keymed Biosciences Co.Ltd
INDUSTRY